All lobbying filings

FARRAGUT PARTNERS LLP

FARRAGUT PARTNERS LLP filed a Q3 report for GILEAD SCIENCES INC. on October 20, 2026, reporting $80,000 in lobbying income.

Lobbying for GILEAD SCIENCES INC. · Pharmaceutical company

All filings by FARRAGUT PARTNERS LLP · Everything GILEAD SCIENCES INC. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$80,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Lobbyists on this filing 7

JEFF MACKINNON

Previously held: LD & LA Rep. Joe Barton (RTexas)
JEFFERY C. MORTIER

Previously held: Prof Staff on E&C Cmte LA Rep Whitfield and Intern Devin Nunes
SARAH WALTER

Previously held: Former Legislative Director/Chief Counsel, Sen. John Breaux
EDWARD WHITFIELD

Previously held: U.S. Representative (21 yrs.)
KRISTEN BAUTZ

Previously held: Senior Advisor and Special Projects Coordinator, Rep Wasserman Shultz
DYLAN MOORE

Previously held: Intern/Staff Assistant, Speaker John Boehner (OH-8); Legislative Assistant/Legislative Director/Deputy Chief of Staff, Rep. Larry Bucshon (IN-8); Intern, Rep. Mike Turner (OH-10)
CONSTANTINE HINGSON

Previously held: Chief of Staff, Senator Dan Coats; Counsel/Legislative Director, Senator Judd Gregg; General Counsel, Senator Elizabeth Dole

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Medicare/Medicaid

Coverage and reimbursement policy for HCV and HIV portfolios. Issues pertaining to the six protected classes. Drug pricing legislation- part D redesign. Issues related to Medicaid drug rebate program. Monitoring CMMI demonstrations

Health Issues

Issues pertaining to the 340B drug discount program.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.